• 1. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 2. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 3. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 4. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Phenylpyrrolidines

Research Brief on 3-Pyrrolidinecarboxylicacid, 4-(4-bromophenyl)-1-(phenylmethyl)- (CAS: 885959-06-8): Recent Advances and Applications

The compound 3-Pyrrolidinecarboxylicacid, 4-(4-bromophenyl)-1-(phenylmethyl)- (CAS: 885959-06-8) has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and emerging roles in drug discovery.

Recent studies highlight the compound's role as a versatile scaffold in the design of small-molecule inhibitors targeting key enzymes involved in inflammatory and oncogenic pathways. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor in the synthesis of novel PDE4 inhibitors, showing promising results in preclinical models of autoimmune diseases. The bromophenyl moiety appears critical for target engagement, while the benzyl group enhances pharmacokinetic properties.

Structural-activity relationship (SAR) studies published in Bioorganic & Medicinal Chemistry Letters (2024) reveal that modifications at the pyrrolidine nitrogen significantly influence binding affinity to G-protein coupled receptors. The 885959-06-8 derivative with a para-bromophenyl substitution exhibited 12-fold greater selectivity for the 5-HT2A receptor compared to earlier analogs, suggesting potential applications in CNS drug development.

Innovative synthetic approaches have been developed to access this scaffold more efficiently. A recent Nature Protocols paper (2024) describes a microwave-assisted, one-pot synthesis method that improves yield from 42% to 78% while reducing reaction time from 18 hours to just 2.5 hours. This advancement addresses previous challenges in large-scale production and has enabled more extensive biological evaluation.

Emerging applications in radiopharmaceuticals have been reported, where the bromine atom in 885959-06-8 serves as an ideal handle for radiohalogenation. Research teams at several institutions are exploring ⁷⁶Br-labeled derivatives for PET imaging of tumor-associated inflammation, with preliminary results showing excellent in vivo stability and target specificity.

The compound's safety profile has been systematically evaluated in recent toxicology studies. A comprehensive ADMET assessment published in Chemical Research in Toxicology (2024) indicates favorable metabolic stability (t_1/2 = 4.2 hours in human liver microsomes) and minimal CYP450 inhibition, positioning it as an attractive lead compound for further optimization.

Looking forward, several pharmaceutical companies have included 885959-06-8 derivatives in their preclinical pipelines, particularly for inflammatory bowel disease and certain hematological malignancies. The compound's unique combination of synthetic accessibility, drug-like properties, and target versatility continues to drive innovative research across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)